Rare pe­di­atric PRV pro­gram not linked to uptick in new drugs start­ing tri­als, study finds

The rare pe­di­atric pri­or­i­ty re­view vouch­er (PRV) pro­gram was not found to be as­so­ci­at­ed with an in­crease in the num­ber or rate of new rare pe­di­atric dis­ease drugs that be­gan clin­i­cal tri­als, a Health Af­fairs study found.

But the re­searchers from Har­vard Med­ical School, work­ing on what they said is the first study on the im­pact of the rare dis­ease PRV pro­gram on drug de­vel­op­ment, al­so found that their da­ta do pro­vide some en­cour­ag­ing news about rare pe­di­atric dis­ease drug de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER